NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

LRRK2 (Leucine-Rich Repeat Kinase 2) Parkinson's Disease Fingerprint

Not Yet RecruitingNA

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Conditions: Parkinsons Disease (PD), LRRK2

Interventions: The interventions of the study are the study of blood biomarkers and neuroimaging and neurophysiological data

The goal of this interventional monocentric study is to identify molecular and clinical markers of LRRK2-related Parkinson's disease through blood markers analysis and deep clinical phenotyping. Patients who meet the inclusion criteria, after signing the informed consent form will be clinically evaluated by a neurologist expert in movement disorders. Eventually, patients will undergo a blood sample collection, a brain MRI, and a high density EEG. All data will be collected using an ad hoc electronic Case Report Form (CRF) developed for the study

Eligibility overview

Sex: ALL

Age: 30 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* age 30-80 years,
* clinically established diagnosis of PD according to the Movement Disorders Society (MDS) diagnostic criteria,
* Hoehn \& Yahr (H\&Y) stage between 1 and 3,
* 10 patients with a LRRK2 associated parkinsonism and 10 with sporadic PD tested with a NGS panel and MLPA for PD associated genes,
* ability to provide informed consent.

Exclusion Criteria:

* Active or history of other neurological disorders,
* active infectious disease or history within the previous 4 weeks,
* continuative therapy (at least 1 week) with NSAIDs or steroids within the previous 12 weeks,
* active malignancy, autoinflammatory or autoimmune diseases or history within the previous 3 years;
* alcohol or drug abuse or dependence
* any contraindication to the execution of the MRI (including claustrophobia).